CLOFIBRATE

/static/temp/default.svg

Search structure


Trade Names	ATROMID-S CLOFIBRATE
Synonyms	AY-61123 Atromid Atromid-s Chlorfenisate Clofibrate Ethyl p-chlorophenoxyisobutyrate ICI 28257 ICI-28257 NSC-79389
Status
Molecule Category	Free-form
ATC	C10AB01
UNII	HPN91K7FU3
EPA CompTox	DTXSID3020336


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KNHUKKLJHYUCFP-UHFFFAOYSA-N
Smiles	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1
InChI	InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C12H15ClO3
Molecular Weight	242.7
AlogP	3.06
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	35.53
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	16.0

Bioactivity

Mechanism of Action	Action	Reference
Peroxisome proliferator-activated receptor alpha agonist	AGONIST	ISBN


Protein: Peroxisome proliferator-activated receptor alpha Description: Peroxisome proliferator-activated receptor alpha Organism : Homo sapiens Q07869 ENSG00000186951

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Auxiliary transport protein Fatty acid binding protein family	-	-	6000-12000	6920	-
Enzyme Oxidoreductase	-	-	-	-	18
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 1 Nuclear hormone receptor subfamily 1 group C Nuclear hormone receptor subfamily 1 group C member 1	55000-55000	-	-	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	115
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	60000-71000	-	-	-

Assay Description	Organism	Bioactivity	Reference
Reduction in serum cholesterol in CF1 mice on day 16 following 20 mg/kg i.p. o.d. for 16 days.	Mus musculus	13.0 %
Reduction in serum cholesterol in CF1 mice on day 9 following 20 mg/kg i.p. o.d. for 16 days.	Mus musculus	12.0 %
Reduction in serum cholesterol in CF1 mice on day 14 following 20 mg/kg i.p. o.d. for 16 days.	Mus musculus	25.0 %
In vitro inhibitory activity against rat microsomal lipid peroxidation (m-LPO)	Rattus norvegicus	1.0 ug.mL-1
Ability to inhibit collagen -induced platelet aggregation in male SD rats; <10	Rattus norvegicus	10.0 %
Toxicity in healthy rat assessed as incidence of drowsy state at 2000 to 7000 mg/kg, po measured after 2 to 6 hrs	Rattus norvegicus	50.0 %
Inhibition of full-length human 11beta-HSD1 expressed in HEK293 cells at 10 uM after 2 hrs by scintillation proximity assay relative to control	Homo sapiens	18.11 %
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	114.71 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	127.7 %
Hypolipidemic activity in Wistar rat assessed as reduction in plasma triglyceride level at 1693 umol/kg/day administered through diet for 10 days	Rattus norvegicus	78.0 %
Hypolipidemic activity in Wistar rat assessed as reduction in plasma triglyceride level at 766 umol/kg/day administered through diet for 10 days	Rattus norvegicus	66.0 %
Hypolipidemic activity in Wistar rat assessed as reduction in plasma triglyceride level at 304 umol/kg/day administered through diet for 10 days	Rattus norvegicus	48.0 %
Hypolipidemic activity in Wistar rat assessed as reduction in plasma triglyceride level at 119 umol/kg/day administered through diet for 10 days	Rattus norvegicus	30.0 %
Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 1693 umol/kg/day administered through diet for 10 days	Rattus norvegicus	41.0 %
Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 766 umol/kg/day administered through diet for 10 days	Rattus norvegicus	36.0 %
Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 304 umol/kg/day administered through diet for 10 days	Rattus norvegicus	18.0 %
Hypolipidemic activity in Wistar rat assessed as reduction in plasma cholesterol level at 119 umol/kg/day administered through diet for 10 days	Rattus norvegicus	9.0 %
Hypolipidemic activity in TritonWR1339-induced hyperlipidemic Kunming mouse model assessed as reduction in plasma TG level at 0.362 mmol/kg, ig administered for 7 days	Mus musculus	25.5 %
Hypolipidemic activity in TritonWR1339-induced hyperlipidemic Kunming mouse model assessed as reduction in plasma TC level at 0.362 mmol/kg, ig administered for 7 days	Mus musculus	21.2 %

Related Entries

Cross References

Resources	Reference
ChEBI	3750
ChEMBL	CHEMBL565
DrugBank	DB00636
DrugCentral	694
FDA SRS	HPN91K7FU3
Human Metabolome Database	HMDB0014774
Guide to Pharmacology	2667
KEGG	C06916
PharmGKB	PA449045
PubChem	2796
SureChEMBL	SCHEMBL2356
ZINC	ZINC000000056648

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).